Animal Health Solutions

When RESTING ITCH FACE Is Staring You Down, Choose Numelvi * Over the other JAK enzymes in in vitro assays. † In a canine interleukin-31 (cIL-31)-induced pruritus model. ‡ A≥2cmreductioninownerPruritusVisualAnalogScale. § Numelvi is taken at or around mealtime. At least 10X more selective for JAK1 1 * Starts reducing itch within 2-4 hours 3 † >82% of dogs showed significant ‡ improvement in itch within 1 week 4 Approved for dogs and puppies as young as 6 months of age and can be used in dogs weighing at least 2 kg Once-daily dosing from day 1 § To Save Now Contact Your Covetrus Representative www.covetrus.vet/numelvi References: 1. Kowalski T, Schuette S. The second-generation Janus kinase inhibitor atinvicitinib is a potent and highly selective inhibitor of JAK1. Vet Dermatol. 2026;0:17. https://doi.org/10.1111/vde.70046 2. Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. Front Immunol. 2022;13:1068260. doi:10.3389/ fimmu.2022.1068260 3. Kowalski T, Prohaczik A, Locke K, et al. The second-generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. Vet Dermatol. 2026;0:17-18. https://doi.org/10.1111/ vde.70046 4. Data on File. Study Summary REF-12964. Merck Animal Health. IMPORTANT SAFETY INFORMATION NUMELVI is not for use in dogs less than 6 months of age or those with serious infections. NUMELVI may increase susceptibility to opportunistic infections, including demodicosis and interdigital furunculosis. Consider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis. NUMELVI is a JAK inhibitor. New neoplastic conditions (benign and malignant) have been reported in dogs treated with other JAK inhibitors. The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days. The safe use of NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs, nor in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. For complete safety information, refer to the product label. TERMS & CONDITIONS Cannot be combined with other offers. Only Numelvi is eligible and qualifies for this rebate. Promotion ends June 30, 2026. To qualify for the "Promotional Rebate," a qualifying clinic must purchase a minimum of $2,500 of Numelvi. Maximum rebate payout for this Promotion Period is $5,000. Qualifying purchase(s) must be ordered within the Promotion Period, and the complete order must be invoiced within 7 days of the end of the Promotion Period. Backordered products are eligible. Returned products are not eligible. Clinic must pay full vet retail price on purchased Numelvi to qualify for rebate. Cumulative orders will apply to a single ship-to location, and the rebate will be paid to the ship-to address on file. Orders may not be split between multiple ship-to locations under different ownership. Offer valid only for veterinary clinics that have a valid Veterinary Patient Client Relationship, as defined by AVMA. Offer available to clinics in the 50 United States or the District of Columbia only. Allow 8–10 weeks for rebate processing (after end of the Promotion Period). Void where prohibited by law. Merck Animal Health reserves the right to cancel or amend this program without notice at any time, for any reason, at its sole discretion. Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-NUM-250800002

• Cover